These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10078765)

  • 21. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
    Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Multiple sclerosis and pregnancy].
    Ruuskanen J; Malm H; Airas L
    Duodecim; 2013; 129(14):1457-64. PubMed ID: 23961604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 29-year-old man with multiple sclerosis, 1 year later.
    Delbanco TL; Hartman EE
    JAMA; 1999 Jun 23-30; 281(24):2329. PubMed ID: 10386558
    [No Abstract]   [Full Text] [Related]  

  • 29. Glatiramer acetate for multiple sclerosis.
    La Mantia L; Munari LM; Lovati R
    Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
    Arnon R; Aharoni R
    J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 35. Glatiramer acetate: a novel therapeutic approach in Crohn's disease?
    Neesse A; Michl P; Kunsch S; Gress TM; Steinkamp M
    Inflamm Bowel Dis; 2009 Jan; 15(1):156-7. PubMed ID: 18626969
    [No Abstract]   [Full Text] [Related]  

  • 36. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
    Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
    J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Zwibel H
    Neurology; 2002 Feb; 58(4):667; author reply 668. PubMed ID: 11865160
    [No Abstract]   [Full Text] [Related]  

  • 38. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.
    Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD
    Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.